English
 

Portfolio News

January 16, 2019
Alpine Immune Sciences Announces $25 Million Private Placement

January 3, 2019
Mindstrong Health Expands Series B Financing with $31M Investment

December 12, 2018
Checkmate Pharmaceuticals Announces CEO Transition and $22 Million Financing

October 30, 2018
Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer

October 1, 2018
VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Clinic

August 8, 2018
Apexigen Raises $73 Million In Series B And Series C Financings

August 3, 2018
IMPACT Therapeutics Raises $30 Million In Series C Financing

July 30, 2018
Omniome Completes $60 Million Series B Financing To Advance Novel Genomic Sequencing Technology

July 17, 2018
Polares Raises $25M to Bring its 'Hemi-Replacement' Mitral Valve to the Clinic

June 14, 2018
Mindstrong Health Announces $15M Series B Round Financing and Business Update

May 10, 2018
Lilly Announces Agreement To Acquire ARMO BioSciences

January 25, 2018
ARMO BioSciences Announces Pricing of Initial Public Offering

December 14, 2017
GRAIL Announces Appointment of Jennifer Cook as Chief Executive Officer

December 8, 2017
EpiMab Biotherapeutics Wins Fortune China Innovation of the Year

November 13, 2017
Arcus Biosciences Announces $107 Million Series C Financing and Initiation of Two Clinical Trials

August 29, 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing

May 31, 2017
GRAIL and Cirina Combine to Create Global Company Focused on Early Detection of Cancer

May 8, 2017
Aadi Bioscience Closes $23 Million in Series A Funding

May 3, 2017
Hummingbird Bioscience Closes a Venture Funding Round of an Undisclosed Amount from Decheng Capital

April 25, 2017
EpimAb Biotherapeutics Raises $25M in Series A Financing From International Consortium to Advance Pipeline of Novel Bispecific Antibodies

April 11, 2017
Nature Biotechnology Features ReadCoor as a 2016 Leading Spinout

April 11, 2017
Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors

December 14, 2016
ReadCoor Receives $2.5M Grant For Novel Pathogen Detection

October 25, 2016
First Scientist to Discover Fetal DNA in Plasma Co-Founds Cirina for Early Detection of Deadly Diseases

September 28, 2016
ReadCoor Announces Launch from Wyss Institute Following Completion of Series A Financing Round

September 27, 2016
SentreHEART Announces Closing of $35M Funding Round for aMAZE Trial

June 1, 2016
AccuraGen Raises $40M in Series B Financing

May 29, 2016
Dennis Lo, Co-founder of Cirina, featured on CNN

August 25, 2015
Becton Dickinson Acquires Single-Cell Genomics Startup Cellular Research

August 13, 2015
Roche Acquires GeneWEAVE for up to $425 Million to Strengthen Offerings in Microbiology Diagnostics

May 26, 2015
3SBio Attracts GIC, BlackRock to $712 Million Hong Kong IPO

February 19, 2015
China's 3SBio Eyes HK Listing Two Years After Going Private

February 11, 2015
Invitae Prices Upsized IPO Above Range at $16

January 9, 2015
Invitae Corporation Files Registration Statement for Proposed Initial Public Offering

October, 13, 2014
Invitae Completes $120 Million Series F Financing

July 2, 2014
GeneWeave Attracts $12 Million to Provide Same-Shift Sample-In/Susceptibility-Out Diagnostic Solutions for Multi-Drug-Resistant Organisms

February 14, 2014
GenapSys Featured on Forbes

November 14, 2013
GenapSys Raises $37M to Commercialize Next Generation Sequencing Platform

February 28, 2012
GeneWeave Biosciences Inks $12M

Decheng Capital News

March 19, 2017
Professor Dennis Lo, Decheng’s Advisor, Received the 2016 Future Science Prize Award

November 14, 2016
Dan Zabrowski Joins Decheng Capital as Venture Partner

September 20, 2016
Hong Kong Professor Dennis Lo Yuk-ming Bags First-ever Chinese Version of Nobel Prize

March 6, 2014
Mr. Robert King, Decheng’s Co-Anchor LP, Received the 2014 Arbuckle Award

June 6, 2013
Decheng Capital celebrates the final closing of USD Fund I

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.